ESC 365 - Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction

ESC Professional Premium Access

Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction

Session: Antithrombotic therapy in acute coronary syndromes and PCI

Topic: Antiplatelet Drugs

Speaker: Doctor S. Godtfredsen (Aalborg, DK)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Sissel Johanne Godtfredsen

Aalborg University Hospital, Aalborg (Denmark)

0 follower

6 more presentations in this session

Pharmacodynamic and pharmacokinetic profiles associated with switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the SWAP-6 study

Speaker: Doctor M. Galli (Rome, IT)

Pattern of dual antiplatelet use and 12-month outcomes stratified by bleeding and ischemic risk in acute coronary syndrome patients undergoing percutaneous coronary intervention

Speaker: Doctor A. Lai (Shatin, HK)

Repeat coronary revascularization in high-risk patients treated with ticagrelor monotherapy after PCI: Insights from the randomized TWILIGHT trial

Speaker: Professor R. Mehran (New York, US)

Mortality with bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome

Speaker: Doctor M. Galli (Rome, IT)

In vitro comparison of platelet aggregation between zalunfiban and selatogrel in healthy donors

Speaker: Mr S. Rikken (Nieuwegein, NL)

Access the full session

Antithrombotic therapy in acute coronary syndromes and PCI

Speakers: Doctor S. Godtfredsen, Doctor M. Galli, Doctor A. Lai, Professor R. Mehran, Doctor M. Galli...

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources